45 results about "Cholinergic system" patented technology

Compounds of formula (I)are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.

Compounds of formula (I) are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.

The invention relates to an application of icaritin to a medicine for treating the Alzheimer disease. Icaritin is taken as a main raw herb, and a proper amount of auxiliary materials are added to prepare an oral preparation or an injection. By deep and detailed research of icaritin on aspects, such as a pharmacological action and an action mechanism, it is found that icaritin can obviously reduce Abeta aggregation and cholinergic nerve functional impairment, due to Abeta<25-35>, of a dementia rat model, and obviously improves the learning and memory dysfunction of the dementia rat model. Icaritin can reduce Abeta aggregation and improves the function of brain cholinergic nerve, produces a function of resisting Abeta<25-35> neurotoxicity, and obviously improves the learning and memory ability of the dementia rat model. According to the invention, by researching the effects of icaritin on the learning and memory ability, the cholinergic system, and an Abeta metabolic pathway of the dementia rat model, the pharmacological action mechanism of icaritin on treating the Alzheimer disease is illustrated, and pharmacological foundations on application of further developing icaritin are provided.

The invention provides medical application of brain and heart beneficial tablets in treatment of Alzheimer's disease, and has the outstanding medical treatment effect. A mice is feed with a brain andheart beneficial tablet water solution, the brain and heart beneficial tablets are proved to have the efficacy of preventing and treating Alzheimer's disease through behavioral experiments (mine test,jump platform test, Y maze test and water maze test), immunohistochemical,serum and cortical brain ELISA measuring and western blot, forming of Abeta plaque in the brain can be reduced, and the pathologic condition of Alzheimer's disease can be improved by adjusting the oxidative stress and cholinergic system.

The invention relates to an active ingredient combination of at least one modulator of the cholinergic system and at least one substance with an anti-excitatory action for treating a dependence on addictive substances or narcotics, in particular for treating alcoholism.

The invention discloses an application of dioscin to preparation of medicines for treating Alzheimer's diseases. The Morris water maze testing result shows that a dioscin administration group can shorten the escaping latency period, prolong original platform quadrant residence time and increase the number of times of passing through a platform, which indicates that the dioscin can significantly improve the spatial learning and memorizing capacity of AD mice; the gait analysis result indicates that the dioscin can significantly increase the gait indexes of the AD mice, and strengthen the physical strength of the AD mice, so that the movement velocity of the AD mice is accelerated, the stride frequency is increased, the stepping length is increased and the duty cycle can be significantly shortened; the dioscin can significantly reduce the MDA level in hippocampal tissue of the AD mice, increase the GSH level and the SOD level, and improve oxidative damage of brain tissue of the AD mice;and the dioscin can restrain AchE activity of the hippocampal tissue, increase ChAT level, influence a cholinergic system, obviously improve the pathology structure of the brain tissue of the AD miceand ultrastructural damage of nerve cells. The dioscin can be used as a single effective component to be prepared into medicines, and can be combined with other medicines for preparing a compound preparation.

The present invention relates to novel pyridylether derivatives which are cholinergic ligands at nicotinic Ach receptors. The compounds of the invention are useful for the treatment of conditions, disorders, or diseases involving the cholinergic system of the central nervous system, pain, inflammatory diseases, diseases caused by smooth muscle contractions and as assistance in the cessation of chemical substance abuse.

The invention discloses application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis. Researches shows that homomangiferin can improve damaged learning and memory ability of APP (amyloid protein precursor) transgenic mice evidently, and can improve relatively-long-term memory in short-term memory of the APP transgenic mice. The homomangiferin can increase content of Ach (acetylcholine), improve activity of CHAT (choline acetyl transferase) and inhibit activity of AchE (acetylcholinesterase), and accordingly indexes in terms of APP transgenic dementia model pathology, cholinergic system, cell apoptosis and the like can be improved. The homomangiferin and homomangiferin compositions can be used for preparing pharmaceuticals for preventing senile dementia and hypomnesis.

The present invention relates to novel N-oxides of certain diazabicyclononylpyrimidine derivatives and their use in the preparation of pharmaceutical compositions. The compounds of the present invention were found to be cholinergic ligands of nicotinic acetylcholine receptors and modulators of monoamine receptors and transporters. Due to their pharmacological properties, the compounds of the present invention can be used in the treatment of different diseases or disorders, for example diseases or disorders involving the cholinergic system of the central nervous system (CNS), peripheral nervous system (PNS), diseases involving smooth muscle contraction or disorder, endocrine disease or disorder, disease or disorder involving neurodegeneration, disease or disorder involving inflammation, pain, and withdrawal symptoms resulting from cessation of chemical substance abuse.

The invention discloses a pharmaceutical composition for enhancing the memory of people rapidly entering plateaus. The pharmaceutical composition is composed of active components and auxiliary materials; the active components are composed of taurine, egg yolk lecithin, acetyl-L-carnitine and huperzine A Composition; The excipients consist of lactose, MCC and magnesium stearate or consist of lactose and magnesium stearate. The beneficial effects of the present invention are as follows: the pharmaceutical composition provided by the present invention for enhancing the memory of people rapidly advancing to plateau provides essential nutrients for nerve cells, scavenging free radicals, supplementing neurotransmitter acetylcholine precursors, and regulating the functions of the central cholinergic system, etc. Starting from different mechanisms of action, they act comprehensively on the body, which embodies the advantages of combined medication and achieves the effect of improving the memory of people who are rapidly entering the plateau.

This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

A method for detecting zebrafish M3 receptor protein based on determination of p38MAPK protein expression comprises the following steps: (1), preparing a zebrafish brain tissue protein sample; (2), performing SDS (sodium dodecyl sulfate) gel electrophoresis; (3), performing film transferring; (4), closing; (5), performing primary and secondary antibody inoculation; (6), performing rendering reaction; (7), calculating M3 receptor variation results. The technical defect that traditional zebrafish M3 receptor detection is limited to zero specific antibody and accordingly is unable to use western immunoblotting is overcome, the use of p38MAPK phosphorylation level to determine changes in zebrafish M3 receptor protein content is provided for the first time, and the method is high in sensitivity, good in stability and free of complex equipment; meanwhile, the method is simple and quick to perform, high in specificity and low in cost; internal acting mechanism of a cholinergic system is studied in terms of molecules, and in connection with study on zebrafish behavior changes, finally water quality can be estimated and monitored online in real time.

The present invention relates to novel 2,5-diazabicyclo[2.2.1]heptane derivatives, which are found to be potent modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

The present invention relates to novel pyridylether derivatives which are cholinergic ligands at nicotinic Ach receptors. The compounds of the invention are useful for the treatment of conditions, disorders, or diseases involving the cholinergic system of the central nervous system, pain, inflammatory diseases, diseases caused by smooth muscle contractions and as assistance in the cessation of chemical substance abuse.

This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

This invention relates to novel triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.